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1  | INTRODUC TION
Baloxavir marboxil is a small molecule inhibitor of the endonuclease 
region in the polymerase acidic (PA) protein of influenza viruses and 
was recently licensed for treatment of influenza in otherwise healthy 
and high-risk individuals in Japan and the United States.1 Analysis 
of viruses obtained from patients following treatment revealed that 
amino acid substitutions at residue 38 of the PA protein (I38T, I38M 
or I38F, referred to as PA/I38X) confer 10-fold to 68-fold reductions 
in baloxavir susceptibility in vitro.2,3 These substitutions are de-
tected at variable frequencies in baloxavir-treated patients, with the 
highest rates in adolescents infected with A(H3N2) viruses, where 
PA/I38X substitutions were identified in 23.4% of patients.2 To date, 
PA/I38T is the most commonly detected substitution and is associ-
ated with the largest reduction in baloxavir susceptibility (50-fold to 
68-fold compared with wild-type virus).2,3
In the 2018/19 influenza season, over six million people were 
treated with baloxavir in Japan and PA/I38X substitutions were re-
ported in 6/335 (1.5%) of A(H1N1pdm09) viruses, 34/356 (9.6%) of 
A(H3N2) and 0/42 of influenza B viruses by The National Institute 
of Infectious Diseases (NIID, Japan). Viruses that contain PA/I38T 
substitutions were also detected in four patients who had not been 
treated with baloxavir, suggesting that variant viruses had transmit-
ted between people.4 Given the current rates of PA/I38X variants 
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Abstract
Baloxavir marboxil is a novel endonuclease inhibitor licensed for treatment of oth-
erwise healthy or high-risk individuals infected with influenza. Viruses with reduced 
baloxavir susceptibility due to amino acid substitutions at residue 38 of the PA have 
been detected in some individuals following treatment. Here, we describe a geno-
typic pyrosequencing method that can be used to rapidly screen circulating influenza 
A and B viruses for substitutions in the PA/I38 codon and to quantify mixed viral 
populations. This method is suitable for surveillance of baloxavir susceptibility and to 
analyse samples from hospitalised patients undergoing baloxavir treatment to aid in 
clinical decision making.
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obtained from baloxavir-treated patients and the potential transmis-
sibility of these viruses, surveillance is important to monitor for the 
emergence of PA/I38X variants in the community. Importantly, rapid 
detection of viruses with reduced antiviral susceptibility in hospi-
talised patients can aid clinicians in selecting appropriate antiviral 
drugs and improve patient management.
Point-of-care tests are available for the rapid detection of influ-
enza infection, however, these tests do not have the capacity to pro-
vide information on the presence of specific amino acid substitutions. 
Therefore, laboratory assays are utilised to determine antiviral suscep-
tibility. Phenotypic assays that directly measure baloxavir susceptibil-
ity have been developed 5-7; however these assays typically require 
cultured isolates, are slow (3-5 days) and relatively low throughput. 
Consequently, rapid genotypic assays which can be performed di-
rectly on clinical specimens are required. Pyrosequencing has been 
previously utilised to detect amino acid substitutions that are known 
to confer reduced susceptibility to M2 ion channel inhibitors and neur-
aminidase inhibitors.8 Here, we outline a pyrosequencing method for 
the detection of PA/I38X variants in A(H3N2), A(H1N1pdm09) and in-
fluenza B viruses and report on the accuracy of sequence analysis and 
estimated mixture proportions.
Full-length PA nucleotide sequences for all circulating influenza 
subtypes/types submitted to the Global Initiative on Sharing All 
Influenza Data (GISAID) database from 2009 to 2018 were down-
loaded. For each virus type/subtype, nucleotide sequences were 
aligned using MAFFT and primer sets were designed such that 
they bound to regions of high similarity (>90% conservation of se-
quences)9 (Table 1). RNA was extracted using the QIAamp Viral 
RNA kit (Qiagen) according to the manufacturer's protocol, and RT-
PCR was conducted using the MyTaq One-Step RT-PCR kit (Bioline) 
and standard thermocycling conditions.10 The PyroMark vacuum 
prep workstation, PyroMark ID Q96 and PyroMark gold reagents 
(Qiagen) were used as previously described.11
The workflow for identifying PA/I38X variants is depicted in 
Figure 1, where the sequence of the PA/I38 codon is determined 
using the “sequence analysis” (SQA) mode of the PyroMarkID Q96. A 
biotinylated PCR product will yield a pyrogram and a nucleotide se-
quence for a short region (approximately 15-30 base pairs) that en-
compasses the single nucleotide polymorphism (SNP) of interest. As 
a result, the presence of an amino acid substitution can be identified. 
As biotin is tagged on the forward primer of the RT-PCR reaction, the 
codons depicted in Figure 1 are in the reverse complement. It is also 
important to note that the codon sequence for the A(H1N1pdm09) 
wild-type PA/I38 was TAT (ATA, forward direction) prior to 2015 but 
has since changed to AAT (ATT, forward direction). Once the nucle-
otide sequence for a virus is obtained and an amino acid substitution 
is detected, the relative proportion of the wild type and variant mix-
ture proportion can be assessed using the “Allele Quantitation (AQ)” 
mode. The AQ mode will estimate the proportion of the two nucle-
otides of interest based on the relative height of the pyrogram peak. 
This additional step is only necessary if detailed mixture analysis is 
required (Figure 1).
The specificity of the pyrosequencing primers was tested with 
60 representative cultured virus isolates (including A(H1N1)pdm09, 
A(H3N2), B/Victoria, B/Yamagata) collected as part of the WHO 
Global Influenza Surveillance and Response System from various 
geographic locations between 2011 and 2018. All viruses were suc-
cessfully amplified by the primers, and SQA analysis indicated that 
all viruses contained the PA/I38 wild-type codon. As part of rou-
tine surveillance, 71 influenza virus isolates circulating in 2019 were 
tested, and all were successfully amplified and shown to contain a 
wild-type codon at PA/I38.
To evaluate the sensitivity and limit of detection of the py-
rosequencing assay, three virus isolates A/Tasmania/501/2018 
(H1N1pdm09), A/Sydney/21/2019 (H3N2) and B/Perth/14/2018 
(B/Yamagata lineage) were titrated in 10-fold dilutions from 105 
to 101 RNA copy number/mL. PyroMarkID SQA software will pro-
vide a “pass,” “check” or “fail” quality score for each sequence. 
SQA analysis was successfully performed with a “pass” quality 
check on all virus types/subtypes until 103 RNA copies/mL. A 
“check” quality score was obtained at 102 RNA copies/mL for all 
virus types; however, a nucleotide sequence was still generated 
by the PyroMark ID software. For sequences generated with the 
“check” quality score, pyrograms need to be visually checked for 
markers of poor quality sequence such as wide peaks, spurious 
peaks, initial baseline drift or overall low signal. At 101 RNA cop-
ies/mL, the pyrosequencing method we have described cannot 
obtain a sequence for all influenza virus types and a “fail” quality 
score was obtained.
Mixed viral populations of wild type (WT) and variant viruses 
can occur in patients undergoing antiviral treatment.12 The accu-
racy of the pyrosequencing assay to detect PA/I38X:WT mixtures 
was tested using DNA plasmids containing the PA segment from 
A/Perth/261/2009 (H1N1pdm09), A/Perth/16/2009 (H3N2) and 
TA B L E  1   RT-PCR and pyrosequencing primer sequences
Influenza type/subtype RT-PCR forward RT-PCR reverse Sequencing
A(H1N1)pdm09 Biotin-CAATCCAATGATCGTCGAGC GGTGCTTCAATAGTGCATTTGG CAAACTTCCAAATGTGTGCA
A(H3N2) Biotin-TTGTCGAACTTGCAGAAAAGGC GCCATTGTTCTGTCTCTCCCCT CATACCTCCAAGTGAGTGCA
Influenza B Biotin-ATACAAAAGGCCAAAAACACAATG GTTCTTTCCCTTGTCCTTCTAATGC GCAAACCTCTAGATGGACRCA
Note: All primers in 5′-3′ orientation. Sequencing primers are in the reverse complement.
Pyrosequencing assays require a standard RT-PCR reaction in conjunction with specific primers designed for amplification of the PA segment that 
encodes codon 38, specifically, nucleotide 38-260 (A(H3N2)), 27-223 (A(H1N1pdm09)) or 40-211 (Influenza B). The forward primer is biotinylated to 
enable binding to streptavidin beads later in the assay.
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B/Yamanashi/166/1998 (B Yamagata lineage) with either a WT or 
variant codon that was generated through site-directed mutagen-
esis. Plasmids were quantified using the Quant-iT™ PicoGreen™ 
assay and tested as unmixed pure stocks or mixtures of WT/variant 
codon plasmids. Samples were quantified using the AQ mode to 
determine the percentage of variant (Table 2). For all viruses, the 
assay was accurate in estimating PA/I38T:WT and PA/I38M:WT 
mixtures, for example the 50% A/Perth/261/2009 PA/i38T mix-
ture was detected as 48.8%. Poor accuracy was detected for PA/
I38F:WT mixtures, where the B/Yamanashi/166/1998 PA/I38F 
50% mixture was detected as 35.8%. The PyroMark ID software 
does not always have the ability to accurately quantify the chro-
matogram peak height of homopolymers, this may cause the poor 
accuracy shown for the influenza A PA/I38F codon for which the 
nucelotide sequence is AAA (reverse complement).13 Mixture pro-
portions were generated for the influenza B PA/I38F:WT but the 
estimate was 10%-15% lower than expected. The error associated 
with estimating pure populations of PA/I38 or PA/I38X is such that 
percentages that are <5% or >95% cannot be accurately quantified 
(Table 2).
To evaluate the accuracy of the mixture proportion estimates at 
low RNA levels, a PA/I38T:WT virus mixture (reverse genetics de-
rived A/Perth/261/2009) was prepared and titrated 10-fold from 
107 to 101 RNA copy number/mL. AQ analysis of these samples 
showed that mixture proportions remained consistent until 103 copy 
number/mL (Table 3).
The main analysis to determine the accuracy of the assay was 
conducted with varying mixtures of plasmids rather than viruses to 
improve the accuracy of mixture preparation. However, when equiv-
alent mixtures of live viruses have been prepared, the assay has per-
formed similarly (data not shown). Laboratories that are establishing 
this assay may wish to validate the primers and assay on clinical ma-
terial from patients.
Pyrosequencing has several benefits for the detection of SNPs 
to infer antiviral susceptibility. It is rapid, high-throughput, easy 
to analyse and can provide the quantification of wild type and 
variant mixtures. The relatively high sensitivity of our assay also 
allows for detection of PA/I38X variants and mixture estimates 
in clinical specimens with low RNA copy numbers and does not 
require a cultured isolate. This allows for a turn-around time of 
F I G U R E  1   Workflow for the identification of PA/I38X variants using pyrosequencing. The PyromarkID system and Pyromark Gold 
reagents in conjunction with the primers in Table 1 are used for the identification of PA/I38X variants in influenza samples. RNA is 
extracted from influenza virus samples and RT-PCR with biotin-tagged primers is used to amplify an approximately 100 base pair segment 
that encompasses the region of interest in the PA protein. Using the sequence analysis mode of the Pyromark ID, a nucleotide sequence 
surrounding codon 38 is obtained. The sequence analysis panel of the diagram depicts PA/I38 and PA/I38T pyrogram, with the y-axis 
as a luminescence measure and the x-axis showing the addition of enzyme (E), substrate (S) and nucleotides A, T, G, C. The peak height 
is representative of nucleotide addition. If a variant is identified, the sample may be further characterised for mixture proportion using 
the allele quantitation mode of the Pyromark ID. Using half volumes of the initial biotinylated PCR product allows the same PCR product 
to be used for both sequence analysis and allele quantitation. Codons are depicted as the reverse complement as the biotin tag for the 
pyrosequencing primers will sequence in the reverse direction
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<4 hours, meaning antiviral treatment of hospitalised patients 
with influenza can be altered in a clinically relevant window if a 
variant is detected. This is important for patients who are treated 
with antivirals for prolonged periods (such as immunocompro-
mised patients) as continual viral shedding under drug selection 
pressure has been shown to select variants with reduced drug 
susceptibility.12
Amino acid substitutions known to confer reduced susceptibility 
to antiviral compounds can also be determined with other genotypic 
methods such as qPCR, Sanger sequencing and next-generation se-
quencing (NGS). Although qPCR is a high-throughput method that 
is widely established in laboratories and is relatively inexpensive, 
the variety of PA/I38X substitutions already observed in clinical 
specimen means that separate assays would be required for each 
potential substitution and the sequence of the PCR products is not 
usually obtained so novel changes at PA/I38X would not be identi-
fied.14 Sanger sequencing is of moderate cost and is accessible but 
requires several days to generate sequences and is relatively inaccu-
rate in assessing viral mixtures.14 NGS has higher accuracy for viral 
mixture quantification but requires extensive sample preparation 
and data analysis.
Pyrosequencing is frequently performed for identifying re-
duced susceptibility to the neuraminidase inhibitors (NA/H275Y) 
and the M2 ion channel inhibitors (M2/S31N), although the equip-
ment is not as commonly available in laboratories as real-time PCR 
thermocyclers.15 The pyrosequencing method described in this 
study can be used for high-throughput screening of circulating in-
fluenza viruses for PA/I38X amino acid substitutions, and further 
analysis for mixtures of PA/I38X and wild-type sequences pro-
vides information on the emergence of variant viruses in patients 
receiving treatment.
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Expected 
variant (%)
Percentage of variant detected by 
pyrosequencing from a mixed population of 
WT and indicated PA/I38X variant
PA/I38T PA/I38M PA/I38F
A(H1N1pdm09) 0 2.4 ± 0.3 0 ± 0 ND
A/Perth/261/2009 25 23.8 ± 0.4 23.3 ± 0.3 ND
 50 48.8 ± 0.5 47.8 ± 0.4 ND
 75 72.7 ± 0.6 72.1 ± 0.3 ND
 100 98.3 ± 0.2 100 ± 0 ND
A(H3N2) 0 0.5 ± 0.7 1.3 ± 0.1 ND
A/Perth/16/2009 25 27.3 ± 0.5 27.2 ± 0.5 ND
 50 52.6 ± 0.3 51.9 ± 0.6 ND
 75 73.9 ± 0.4 74.3 ± 0.1 ND
 100 98.3 ± 0.4 99.3 ± 0.5 ND
B/Yamagata lineage 0 1.2 ± 1.7 0.4 ± 0.6 0 ± 0
B/Yamanashi/166/1998 25 31.7 ± 0.4 25.8 ± 0.5 9.5 ± 1.3
 50 49.7 ± 0.4 47.5 ± 0.5 35.8 ± 5.5
 75 71.6 ± 0.2 72.1 ± 0.5 63.7 ± 3.2
 100 98.4 ± 1.7 100 ± 0 100 ± 0
Note: Not determined (ND) - AQ analysis could not be performed by PyroMarkID software.
Variant percentages are the average ± standard deviation of three experiments.
TA B L E  2   Accuracy of mixture 
estimates by the AQ pyrosequencing 
assay across different influenza virus 
types/subtype and PA/I38 substitutions
TA B L E  3   Limit of accuracy for AQ analysis
RNA copy number/mL
Proportion of PA/I38T 
(%)
PyroMark ID 
quality score
107 36.6 ± 0.8 Pass
106 36.6 ± 0.9 Pass
105 38.0 ± 2.5 Pass
104 38.6 ± 0.4 Pass
103 39.3 ± 0.2 Pass
102 59.2 ± 2.0 Check
101 27.2 ± 25.7 Fail
Note: PA/I38T proportions are the average ± standard deviation of 
three experiments.
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